Subjects with any previous clinical evidence or history
of severe cardiac, pulmonary, gastrointestinal, renal,
hepatic or neurological disorders were not included in
the trial. Subjects with history of allergy to
aspirin/NSAlDs or who had undergone total knee
replacement in the contra lateral knee in preceding 6
months were excluded. Subjects who had received an
intraarticular corticosteroid injection in a lower joint
during the foregoing three months were not considered.
Also not considered were patients with isolated lateral
compartment disease defined by joint space loss in the
lateral compartment only or who have received
chondrocyte transplants in any lower extremity joint.
Similarly, subjects with comorbid conditions restricting
knee function or on treatment with corticosteroids or
with infectious arthritis or gout were discarded.